ASX:CYC Cyclopharm (CYC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cyclopharm Stock (ASX:CYC) 30 days 90 days 365 days Advanced Chart Get Cyclopharm alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume10,000 shsAverage VolumeN/AMarket CapitalizationA$219.50 millionP/E RatioN/ADividend Yield0.74%Price TargetN/AConsensus RatingN/A Company Overview Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia. Read More Receive CYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address CYC Stock News HeadlinesCyclopharm Limited Secures Shareholder Approval for Key Resolutions at AGMMay 29, 2025 | tipranks.comCyclopharm Limited Expands US Market Presence with Technegas™May 29, 2025 | tipranks.comElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025. | Banyan Hill Publishing (Ad)Cyclopharm Achieves Record Sales with US Expansion in 2024May 29, 2025 | tipranks.comCyclopharm Limited Releases Cautious Financial ProjectionsMay 29, 2025 | tipranks.comCyclopharm Limited Announces 2025 Annual General MeetingApril 29, 2025 | tipranks.comCyclopharm to Present at NWR Virtual Healthcare ConferenceMarch 18, 2025 | tipranks.comCyclopharm to Provide Key Business Update on March 19, 2025March 16, 2025 | tipranks.comSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:CYC CIKN/A Webwww.cyclopharm.com.au Phone61 2 9541 0411FaxN/AEmployees87Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$9.32 million Net Margins-40.69% Pretax MarginN/A Return on Equity-23.34% Return on Assets-15.37% Debt Debt-to-Equity Ratio11.72 Current Ratio4.38 Quick Ratio4.68 Sales & Book Value Annual SalesA$24.06 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow8.40 Book ValueA$0.50 per share Price / BookN/AMiscellaneous Outstanding Shares111,140,000Free FloatN/AMarket CapA$219.50 million OptionableNot Optionable Beta0.70 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (ASX:CYC) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclopharm Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclopharm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.